TECH
NasdaqGSBio-Techne Corporation
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 30 recent filings. 29 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 600 | — | — | 2026-06-02 |
Crouse Steven C. President - Diag & Spatial Bi | Tax withholding | 216 | $49.77 | $10,750.32 | 2026-06-02 |
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 600 | $0.00 | — | 2026-06-02 |
Herr Amy E. Director | Option exercise | 6.64K | $47.60 | $315,873.60 | 2026-05-08 |
Herr Amy E. Director | Sell (open market) | 6.64K | $48.28 | $320,386.08 | 2026-05-08 |
Herr Amy E. Director | Option exercise | 6.64K | $0.00 | — | 2026-05-08 |
Hippel James CFO | Option exercise | 62K | $47.60 | $2,951,200.00 | 2026-05-05 |
Hippel James CFO | Tax withholding | 56.96K | $56.68 | $3,228,209.40 | 2026-05-05 |
Hippel James CFO | Option exercise | 62K | $0.00 | — | 2026-05-05 |
Bohnen Shane SVP - General Counsel | Option exercise | 8.4K | $47.60 | $399,840.00 | 2026-05-05 |
Bohnen Shane SVP - General Counsel | Tax withholding | 7.06K | $56.68 | $399,877.40 | 2026-05-05 |
Bohnen Shane SVP - General Counsel | Option exercise | 8.4K | $0.00 | — | 2026-05-05 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 26.69K | $47.60 | $1,270,539.20 | 2026-05-05 |
Kelderman Kim Director, Chief Executive Officer | Tax withholding | 23.95K | $56.68 | $1,357,542.68 | 2026-05-05 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 26.69K | $0.00 | — | 2026-05-05 |
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 794 | — | — | 2026-05-01 |
Crouse Steven C. President - Diag & Spatial Bi | Tax withholding | 311 | $55.02 | $17,111.22 | 2026-05-01 |
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 794 | $0.00 | — | 2026-05-01 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 11.34K | $0.00 | — | 2026-04-22 |
Kelderman Kim Director, Chief Executive Officer | Tax withholding | 1.36K | $58.58 | $79,844.54 | 2026-04-22 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 11.34K | $0.00 | — | 2026-04-22 |
Hippel James CFO | Option exercise | 62K | $0.00 | — | 2026-04-22 |
Hippel James CFO | Tax withholding | 56.1K | $58.58 | $3,286,162.26 | 2026-04-22 |
Hippel James CFO | Option exercise | 62K | $0.00 | — | 2026-04-22 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 36.5K | $0.00 | — | 2026-04-14 |
Kelderman Kim Director, Chief Executive Officer | Tax withholding | 32.09K | $58.66 | $1,882,282.08 | 2026-04-14 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 36.5K | $0.00 | — | 2026-04-14 |
Bohnen Shane SVP - General Counsel | Option exercise | 2.26K | $0.00 | — | 2026-04-03 |
Bohnen Shane SVP - General Counsel | Tax withholding | 740 | $53.13 | $39,316.20 | 2026-04-03 |
Bohnen Shane SVP - General Counsel | Option exercise | 2.26K | $0.00 | — | 2026-04-03 |
Source: SEC EDGAR Forms 4/4A (CIK 842023). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$ALT $APGE $FOLD $TECH $TERN
$ALT $APGE $FOLD $TECH $TERN So, in your Tern chart, short interest increased over a 6 month period by 1.5-2.5 times its SI 6 months earlier. Wow. Then hit Not fairy tale gobbledygook. Legitimate. Market. Analysis. 👏👏👏👏👏👏👏👏👏👏
$ALT $APGE $FOLD $TECH Short interest of $TERN kept growing and were running into Merck s BO- Offer on March 25 😉👇
$ALT $APGE $FOLD $TECH Trade, interesting thoughts on WHY we see rising short interest and an increase in Bashers ahead of BO news…
$ALT $APGE $FOLD $TECH What I can tell you without any more dd, Dilution is not uncommon before a deal. Basta!
$ALT $TECH $APGE $FOLD interesting. Have you matched it with the available shares of those companies? Maybe it's just that they diluted too and mire available shares meant more shorting? Or dilution means upcoming buyout?
$ALT $APGE $FOLD $TECH Trade, that’s a HELLUVA find. Great job man….🙏🙏😎😎
$ALT $APGE $FOLD $TECH For FSDdingsbums… 👇 @Hatrak1
$ALT Regarding the question about growing short interest: I’ve noticed several times that short interest increased significantly and kept rising right up until the buyout of certain biotech companies. I asked ChatGPT to list the major biotech buyouts in 2026. The results are $TECH, $APGE, and $FOLD. Interestingly, all of them showed elevated or growing short interest leading up to the acquisition announcement. 👇
$TECH TECH Price Target Alert: $73.00. Issued by Deutsche Bank https://marketwirenews.com/stock/tech/news/tech-price-target-alert-73-00-issued-by-deutsche-ban-5447941763202062.html?utm_source=stocktwits
$TECH Hold Recommendation Issued On TECH By Deutsche Bank https://marketwirenews.com/stock/tech/news/hold-recommendation-issued-on-tech-by-deutsche-bank-5939493996299149.html?utm_source=stocktwits
$AYI +21.5% $TECH +20.09% $MU +15.78% $SNDK +17.4% $QCOM +9% to +10% https://truthsandnews.com/markets/top-stock-gainers-today-june-25-2026
Latest news
What to Expect From Bio-Techne's Next Quarterly Earnings Report
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
RBC Capital Downgrades Bio-Techne to Sector Perform From Outperform, Adjusts Price Target to $73 From $62
Bio-Techne Expands AI-Engineered Designer Protein Portfolio
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
Evercore ISI Downgrades Bio-Techne to In Line From Outperform, Maintains $73 Price Target
SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation
Piper Sandler Adjusts Bio-Techne Price Target to $73 From $60, Maintains Neutral Rating
Benchmark Downgrades Bio-Techne to Hold From Buy
TD Cowen Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $65
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.